Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial

Abstract Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalcetide in HD patients. Methods One hundred and thir...

Cijeli opis

Bibliografski detalji

Glavni autori:	Yuka Kurokawa, Yusuke Kaida, Takuma Hazama, Yosuke Nakayama, Takaomi Otome, Ryo Shibata, Sakuya Ito, Goh Kodama, Nao Nakamura, Takatoshi Kambe, Tomofumi Moriyama, Akiko Nagata, Aki Minami, Ryotaro Ando, Yoshifumi Wada, Miki Sugiyama, Michiaki Usui, Michio Chiba, Atsuo Moriyama, Atsuko Ohara, Hiroshi Miyazaki, Tatsuyuki Kakuma, Kei Fukami
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2020-12-01
Serija:	Renal Replacement Therapy
Teme:	Cinacalcet Etelcalcetide Hemodialysis Intact-PTH Secondary hyperparathyroidism
Online pristup:	https://doi.org/10.1186/s41100-020-00310-y
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!